STAT+: Pharmalittle: Biogen is perilously poised for the future; WTO advances controversial Covid-vaccine patent waiver
Top of the morning to you. The middle of the week is upon us and,…
Category: Pharmalot
STAT+: A compromise on patent waivers for Covid-19 vaccines takes a key step at the WTO
A controversial proposal before the World Trade Organization to waive patent rights for Covid-19 vaccines…
STAT+: Pharmalittle: Biogen CEO exits amid Aduhelm failures; FDA eschews its own outside expert panels
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT+: Is the FDA taking advice from its expert panels? A new analysis points to inconsistencies in the process
For decades, the U.S. Food and Drug Administration has relied on outside expert panels for…
STAT+: U.N. committee urges wealthy nations to honor human rights conventions, widen access to Covid vaccines
A United Nations committee urged wealthy nations to support a proposal before the World Trade…
STAT+: Pharmalittle: FDA declines to approve two more drugs tested in China; Pfizer Covid pill fails to prevent infection in household members
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: U.S. Trade Rep report sparks concern that a new clash may occur over clinical trial transparency
A recent Biden administration report on “significant” foreign barriers to U.S. exports suggests that a…
STAT+: Pharmalittle: Investors reject proposals for Covid vaccine makers to share know-how; CMS head says Alzheimer’s drug decision is rare
And so, another working week will soon draw to a close. Not a moment too…
STAT+: The revolving door swings again as Lupin hires an FDA official who oversaw problems at a key plant
The revolving door between the U.S. Food and Drug Administration and the pharmaceutical industry turned…
STAT+: California fines an OptumRx pharmacy for jeopardizing patient health. Is that enough?
The California Board of Pharmacy fined OptumRx, one of the largest pharmacy benefit managers in…
STAT+: Pharmalittle: Amgen faces $7B IRS back-tax bill and fine; McKinsey exec apologizes for opioid work during hearing
Rise and shine. Another busy day is on the way. Indeed, the official to-do list…
STAT+: Pharmalittle: J&J sues wholesalers and a pharmacy over fake HIV meds; Rite Aid to pay $123 million to Humana for inflating drug prices
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Usual and customary? Rite Aid ordered to pay Humana $123 million for inflating pharmacy claims
Rite Aid was ordered by an arbitrator to pay nearly $123 million to Humana, one…
STAT+: Pharmalittle: White House announces Covid-pill push; ‘right-to-try’ think tank is back with a new law
Top of the morning to you. Gray skies are hovering over the Pharmalot campus right…
STAT+: Thanks to Covid-19, pharma’s reputation improved among patient groups. But can it last?
Thanks to its response to the Covid-19 pandemic, the pharmaceutical industry has greatly improved its…
STAT+: Biden is urged to pursue march-in rights for a pricey cancer drug after NIH delays a petition review
Citing arguments by more than two dozen legal experts, Sen. Elizabeth Warren (D-Mass.) is urging…
STAT+: One in four pharma status reports on follow-up trials are late or aren’t filed
Drug companies failed to submit 11% of status reports for clinical trials they were required…
STAT+: Pharma R&D payments to European researchers are like ‘dark money’
Due to inadequate disclosure policies, drug company payments to European researchers and institutions for R&D…
STAT+: Pharmalittle: Are new ADHD treatments really any better? India moves to reduce dependence on China for pharma ingredients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: U.S. health agency workers fail to report political interference; Canada walks back some drug-pricing reforms
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: U.S. spending on medicines rose 12% last year; Louisiana sues a PBM for allegedly overcharging
Top of the morning to you. And a fine one it is. Blue skies and…
STAT+: U.S. spending on pharmaceuticals jumped 12% in 2021, fueled by costs of Covid-19 vaccines and therapies
Thanks to Covid-19 vaccines and therapies, U.S. spending on pharmaceuticals rose 12% in 2021 as…
STAT+: Endo wins a reprieve in an opioid lawsuit in Tennessee as appeals court overturns sanctions
Endo International won a key battle over its role in the opioid crisis in Tennessee…
STAT+: Louisiana accuses UnitedHealth and its OptumRx PBM of inflating drug costs for its Medicaid program
In the latest bid to pull back the curtain on pharmacy benefit managers, the Louisiana…
STAT+: Pfizer faces criticism for arguing that intellectual property for its Covid-19 pill is a human right
Numerous advocacy groups and institutional shareholders are chiding Pfizer for arguing that its intellectual property…
STAT+: Pharmalittle: Glaxo workers in the U.K. vote to strike; Alabama reaches $276 million deal over opioid crisis
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Pharmalittle: Global demand for Pfizer Covid-19 pill falls; biotech hub in Massachusetts set for a correction
Rise and shine, everyone, a busy day is on the way. We can tell thanks…
STAT+: Animal rights group urges USDA to probe research facilities for failing to inspect monkey shipments
A prominent animal rights group asked U.S. authorities to investigate leading medical research labs for…
STAT+: Pharmalittle: U.K watchdog agency is urged to bolster conflicts policy; FDA device program helps makers more than patients
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: WTO head says Covid vaccine IP talks are nearing agreement; RSV is the next big target for vaccine makers
And so, another working will soon draw to a close. Not a moment too soon,…
STAT+: Bristol Myers agrees to settle lawsuit alleging anti-competitive deals involving HIV drugs
After three years of squabbling, Bristol Myers Squibb has agreed to pay up to $11…
STAT+: Pharmalittle: Justice Department probes Bausch over marketing; Pfizer to seek Covid booster for healthy 5- to 11-year-olds
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Justice Department probes Bausch Health over marketing for dermatology drugs
Bausch Health is being investigated by U.S. authorities in connection with marketing of four medicines…
STAT+: Pharmalittle: U.K. advances novel payment system for antibiotics; Glaxo to pay $1.9 billion for Sierra Oncology
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: A $2.1 million price tag for Bluebird Bio’s gene therapy is cost-effective, analysis finds
As the U.S. health care system braces for expensive gene therapies, a new analysis suggests…
STAT+: Pharma pledges faster drug launches in Europe in hopes of avoiding stricter regulations
In a bid to thwart stricter regulation, the European pharmaceutical industry trade group pledged to…
STAT+: U.K. readies a Netflix-style subscription payment model for badly needed antibiotics
Amid rising concern over antimicrobial resistance, the U.K. has taken a major step toward becoming…
STAT+: Pharmalittle: Will Biogen sue CMS over Alzheimer’s drug coverage? Novartis plans to lay off thousands
Hello, everyone, and how are you this morning? A spot of rain is falling on…
STAT+: FDA scolds Bausch Health for misleading claims about a psoriasis cream
The U.S. Food and Drug Administration has scolded Bausch Health for a video and webpage…
STAT+: Pharmalittle: Lilly and Eisai will still seek accelerated approval for Alzheimer’s drugs; CAR-T cells may shrink some solid tumors
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Medicare finalizes plan for controversial Alzheimer’s drug; advocacy group faces controversy over CMS proposal
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Advocacy group’s advisory board members defect over Biogen Alzheimer’s drug
The furious debate over Biogen’s Alzheimer’s treatment has now sparked controversy over the Alliance for…
STAT+: Pharmalittle: Low-income Part D beneficiaries without subsidies often don’t fill scripts; Pfizer strikes a deal for RSV drugs
Hello, everyone, and how are you today? Gray skies are hovering over the chilly Pharmalot…
STAT+: Many Medicare Part D beneficiaries don’t fill prescriptions for high-priced medicines
Medicare Part D beneficiaries who have low incomes and receive government subsidies were nearly twice…
STAT+: Pharmalittle: Most Americans would get a second booster shot; FDA pulls Glaxo Covid treatment
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: STAT-Harris Poll: Most Americans would get a Covid-19 booster shot if recommended
As a Food and Drug Administration panel meets Wednesday to sort out the ongoing use…
STAT+: Colombian government faces calls to issue compulsory license for Pfizer’s Covid-19 pill
In the latest bid to expand access to the Pfizer Covid-19 pill, several advocacy groups…
STAT+: Pharmalittle: Bluebird axes nearly one-third of its employees; Senate committee probes Merck’s tax practices
Hello, everyone, and how are you today? A cloudy cover greeted us this morning, but…
STAT+: Wyden wants details on Merck’s U.S. taxes as part of expanding probe into pharma practices
The head of the U.S. Senate Finance Committee is seeking details from Merck about the…
STAT+: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible
Amid ongoing debate over biosimilar use in the United States, a new government analysis found…